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Abstract
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers.  Gold standard is represented by the association of platinum- taxane -based 
chemotherapy and radical surgery. Despite several adjustments occurred in cytotoxic drug in last decades, most patients continue to relapse, and no significant 
enhancement has been reached in the overall survival. The development of drug resistance and the recurrence of disease have prompted the investigations of other 
targets that can be used in the treatment of ovarian cancers. Among such targets, polyadenosine diphosphate-ribose polymerase (PARP) represents a novel way to 
target specific patways involved in tumor growth. PARP accelerates the reaction of the polyADP-ribosylation of proteins implicated in DNA repair. PARP inhibitors 
have shown activity in cancers with BRCA mutations, with other deficient DNA repair genes or signaling pathways that modulate DNA repair, or in association 
with DNA damaging agents not involved in DNA repair dysfunction. A number of inhibitors for PARP has been developed, and such drugs are under investigation 
in clinical trials to identify their impact in the treatment of ovarian cancers. This review aims to summarize the recent researches and clinical progress on PARP 
inhibitors as novel target agents in ovarian cancer. 
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Introduction
Despite several improvements in gynaecological 
malignancy scenario, ovarian cancer still  represents the 
most important cause of women cancer–related mortal-
ity, with a 5-year overall survival rate of approximately 
49.7%, ranging from 47% to 19% for advanced stages 
when most patients are diagnosed (1). The combination 
of radical surgery and platinum-taxane-based chemo-
therapy is originally effective, however most patients re-
lapse and develop drug-resistant disease. The poor out-
come of advanced ovarian cancer under conventional 
therapy and the lack of effective chemotherapeutic regi-
mens at recurrence have led to the exploration of new 
strategies that are mainly oriented into planning chemo-
therapy upfront when disease presented uncompletely 
resectable (2), changing of dose and schedule of various 
chemotherapeutic agents (3), and the research on mo-
lecular targeting drugs with or without chemotherapy 
(4), as well as immunotherapy (5). Lately, target thera-
pies have gained great attention, because such therapies 
interfere solely with specific molecular targets, holding 
the promise of greater selectivity and lower toxicities 
(6-8).
Translational research in cancer has recently reached 
many goals in understanding DNA repair pathways in 
order to developing target therapy.  A novel group of 
chemotherapeutic agents consists of polyadenosine 
diphosphate-ribose polymerase (PARP) inhibitors. 
These therapies have been investigated in several can-
cers. In particular, phase II clinical trials have demon-
strated promising results in women affected by heredi-
tary breast and ovarian cancers linked with BRCA1 and 
BRCA2 (referred as BRCA1/2) mutations (9). This 
review summarizes the recent researches and clinical 
progress on PARP inhibitors as novel targeting agents 
in ovarian cancer. 
PARP inhibitors and synthetic lethality 
PARP is an enzymatic complex that was firstly dis-
covered in 1963. However, the potential of PARP in-
hibition to increase DNA damage caused by cytotoxic 
chemotherapy was first speculated in 1980.
PARP-1 and PARP-2 represent the best-character-
ized subtypes of the 17 members of the PARP super 
family (10).
PARP-1 is expressed in all nucleated human cells 
except neutrophils and has been demonstrated be over-
expressed in some tumor types (11). Its expression has 
also been related with overall prognosis in cancer, par-
ticularly for breast cancer (12).
Each cell has a series of pathways to protect its ge-
nome from DNA damage. DNA injury appears as result 
of cell cycling, endogenous events, or cytotoxic agents. 
Once DNA damage alterations occur in these DNA re-
pair pathways, there is an augmented risk of malignant 
transformation and resistance to chemotherapy.
Schematically, DNA repair can be categorized into 
single- stranded DNA-binding proteins (SSB), which 
include base excision repair (BER), nucleotide exci-
sion repair, and mismatch excision repair, or double-
strand breaks (DSB), which comprise non-homolo-
gous end-joining and homologous recombination repair 
(HRR).
PARPs are implicated in DNA repair that utilizes the 
BER pathway (13) and share enzymatic and scaffolding 
properties.
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In fact, DNA damage stimulates the catalytic (14-15) 
activity of PARP-1, which by two zinc finger motifs in 
the DNA-binding domain binds to DNA SSB, thus acti-
vating the BER machinery to repair the SSB. Therefore, 
inhibition of PARP blocks the BER pathway.
Normal cells can restore the DNA injury using dif-
ferent pathways, habitually the homologous recombina-
tion (HR) pathway, a route in which an intricate ma-
chinery is built to permit the sister chromatid to act as a 
specimen for the DNA repair process.
In contrast, in BRCA-mutated ovarian cancer 
cells that missed both copies of BRCA1 or BRCA2, 
DNA damage advances and leads to cell death. Non-
cancer cells, less subjected to DNA damage, are hete-
rozygous for the defect, with one functional allele, and 
consequently retain BRCA1/2 protein expression and 
maintain the HR pathway (see Figure 1).
This dissimilarity between tumor and normal cells 
means that PARP inhibitors eliminate tumor cells selec-
tively compared to the effects in normal cells. This has 
led to the idea of ‘synthetic lethality,’ which means 
that one pathway is mutated in the cancer cell and the 
other pathway is blocked by the drugs. Individually, not 
even the pathway is fundamental, but when both are an-
nulled the cell cannot survive (16). 
PARP inhibitors in hereditary and sporadic ova-
ian cancers
BRCA1 and BRCA2 proteins have a central role via 
homologous recombination in the complex of DNA re-
pair machinery, whereas PARP is the key component in 
BER of DNA.
PARP inhibitors have shown encouraging efficacy 
results in BRCA-mutated ovarian cancer, which repre-
sents approximately 10% to 15% of epithelial ovarian 
cancer (EOC).
BRCA1 has a multidimensional role in DNA repair, 
cell cycle checkpoints, transcription, chromatin remod-
eling, and ubiquitination (17). In spite of its wide roles 
in DNA damage response, BRCA1 is indispensable for 
HRR by contribution in initial DSB processing while 
BRCA2 has a more precise role in the regulation of 
Rad51 recombinase, a key mediator of HRR.
Absence in either BRCA1 or BRCA2 function 
brings to an amplified use of error-prone and mutagenic 
non- homologous end-joining repair (18). Consequent-
ly, loss-of-function mutations in the BRCA1 or BRCA2 
gene augment genome instability that causes hereditary 
ovarian carcinogenesis.
Furthermore, the phenomenon of ‘BRCAness,’ char-
acterized by HR deficiency, should be underlined: up to 
50% of women with high-grade EOC could have func-
tional loss of proteins implicated in the HRR pathways 
of DNA repair, and consequently these tumors will phe-
notypically work like BRCA1/2 mutant cancers, even if 
they do not have specific mutations. In vitro experiments 
have demonstrated that inhibition of the PARP enzyme, 
which is implicated in the base excision DNA repair 
pathway, results in the lack of DNA repair and death in 
cells exhibiting defective HR (19).
Current data propose that sporadic high-grade 
EOCs can allow developed genetic and epigenetic de-
fects in BRCA and in other DNA repair genes that may 
contribute to the ‘BRCAness profile’ associated with an 
improved prognosis after platinum-based chemothera-
py, even in absence of gBRCA1/2 mutations. Several 
major processes seem to be involved in the development 
of the BRCAness pattern. The BRCA1 promoter hyper-
methylation has been shown to lead to BRCA1 silenc-
ing in 5% to 30% of cases (9). Other defective genetic 
factors who affect or are affected by normal BRCA gene 
have been investigated, including the amplification of 
EMSY that brings to BRCA silencing in 20% of cases 
(10). Furthermore, BRCA collaborates with the proteins 
of the Fanconi anemia (FA) complex in the pathway 
of DNA repair, and consequently defects in members 
of the FA complex have been shown to reproduce the 
BRCA-deficient phenotype (11). Other proteins impli-
cated in DNA repair in addition to BRCA could also 
lead to the BRCAness profile in over 10% of cases: hy-
permethylation of Rad51C, a protein that traces DNA 
repair machinery to the damaged strand; mutation/de-
letion in ATM, ATR, and PTEN, which is involved in 
transcription regulation of Rad51(9). Nonetheless, the 
evidence of involved mechanisms is still fragmented, 
and the idea of BRCAness for patients with the sporadic 
form of the disease has not found a concrete base, yet. 
The precise characterization of the BRCAness phe-
notype in high-grade EOC represents today a pivotal 
challenge to enable patients to access new therapeu-
tic strategies, thus impacting the survival perspective. 
Based on the above preclinical data on observed syn-
thetic lethality in BRAC1/2-deficient cancers, a num-
ber of PARP inhibitors have been developed for clinical 
use by various pharmaceutical companies. At present, 
the most investigated PARP inhibitor is olaparib, which 
has shown promising results. An increasing number of 
clinical trials on iniparib, veliparib, rucaparib, niraparib, 
and BMN673 are also underway in gynecological ma-
lignancies, and many phase I and II studies are currently 
ongoing (Table 1). 
Figure 1. DNA repair and PARP inhibitors mechanism. DNA 
damage by ionizing radiation, alkylating agents, topoisomerase 
inhibitors, replication inhibitors and antimetabolites may induce 
double- strand breaks. PARP inhibition impairs the base excision 
repair (BER) pathway. In cells with deficient homologous recom-
bination (HR) pathway, like BRCA-mutated cancer cells, which 
have lost both copies of BRCA1/2, DNA damage accumulates, lead-
ing to programmed cellular death. Non-cancer cells, less subjected 
to DNA damage, are heterozygous for the defect, with one func-
tional allele, and therefore retain BRCA1/2 protein expression and 
maintain homologous recombination pathway. BER: Base excision 
repair; DSB: Double-strand break; HR: Homologous recombination; 
SSB: Single-strand break.
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PARP Inhibitor Phase of Development Combination Type of tumor Status of study
OLAPARIB (AZD2281) 1 Cisplatin, Gemcitabine S C
1 Carboplatin, Paclitaxel S A
1 Carboplatin CC, OC Rec
1 Topotecan S C
1 None S C
1 Carboplatin OC Rec
1 None OC Rec
1 None OC A
1 Cisplatin S A
1-2 Cediranib OC A
2 None OC, TC W
2 None OC C
2 Doxorubicin OC A
2 Carboplatin, Paclitaxel OC A
2 None OC A
2 Carboplatin, Paclitaxel OC A
2 None OC A
2 None OC, PC, PrC, BC C
2 Carboplatin, Paclitaxel OC C
INIPARIB  (BSI-201) 1 None S C
1 Gemcitabine, Carboplatin, Paclitaxel, Doxorubicin S Rec
1 Irinotecan S C
2 None OC C
2 Carboplatin, Gemcitabine OC C
2 Carboplatin, Paclitaxel US C
2 Carboplatin, Gemcitabine OC A
VELIPARIB  (ABT-888) 1 None S C
1 Carboplatin, paclitaxel, bevacizumab, ABT-888 OC,TC,P Rec
1 Doxorubicin OC U
1 Mitomycin C S Rec
1 Dinaciclib with or without Carboplatin S Rec
1 Carboplatin,Paclitaxel, Bevacizumab OC, TC Rec
1 Radiation therapy S with peritoneal carcinomatosis C
1 Carboplatin, Gemcitabine S Rec
1 Paclitaxel, Carboplatin S Rec
1 Gemcitabine S Rec
1 Topotecan S C
1 Temozolomide OC C
1 Bevacizumab,Carboplatin, Cisplatin, Paclitaxel OC Rec
1 Carboplatin, Paclitaxel OC Rec
1 Carboplatin, Gemcitabine S Rec
1 Floxuridine OC, TC Rec
1 Doxorubicin, Carboplatin OC,TC Rec
1 Oxaliplatin, Capecitabine S Rec
1-2 Topotecan OC, S A
1-2 Topotecan OC Rec
2 Temozolomide or Doxorubicin OC A
2 None OC Rec
2 Ciclofosfamide OC A
RUCAPARIB 2 Platinum based chemotherapy Relapsed OC,TC,P Rec
NIRAPARIB 3 None OC Rec
BMN 673 1 None S, OC Rec
Table 1. Ongoing phase I-II clinical trials of polyadenosine diphosphate- ribose polymerase inhibitors (Olaparib, Iniparib, Veliparib, 
Rucaparib,Niraparib, BMN 673) as single agent or in combination with other agents.
S: solid tumors; OC: ovarian cancer; CC: cervical cancer; PrC: prostate cancer; PC: pancreatic cancer; BC: breast cancer; TC: tubal cancer; US: 
uterine carcinosarcoma; Rec: recruiting; A: active not recruiting; C: completed; T: terminated; W: withdrawn; U: unknown
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Olaparib and ovarian cancer 
Pharmacodynamics, pharmacokinetics, and metabo-
lism 
Olaparib (AZD2281, KU-0059436) is a strong in-
hibitor of PARP that provokes synthetic lethality in 
BRCA1/2-deficient tumor cells.
It is being developed as oral monotherapy and 
for combination schedules with other anticancer agents.
The median effective concentration necessary to in-
duce a 50% effect (EC50) of olaparib is approximately 
6 nM. In cancer patients, following a single capsule 
oral dose, olaparib was rapidly absorbed. Exposure in-
creased proportionally with doses up to 100 mg twice 
daily but augmented in a less proportional fashion at 
higher doses. Following dosing to cancer patients at 
doses of 400 mg bid (twice daily), the population es-
timated maximum plasma concentration at steady state 
(Cmax ss) ranged from 1.45 to 11.0 μg/mL (17). Drug-
related material was eliminated in the urine (35%-50%) 
and in the feces (12%-60%), with 10% to 20% and 0.6% 
to 14% of the dosed material recovered as unchanged 
drug in the urine and feces, respectively (21). 
Clinical development 
Phase I-II studies 
‘Synthetic lethality’ concept  was firstly tested in a 
phase I trial by Fong et al. with a dose escalation of 
olaparib from 10 mg daily to 600 mg twice daily in 
a population of patients affected by recurrent/refrac-
tory tumors including EOC (22). Sixty patients were re-
cruited: 22 (37%) were carriers of a BRCA1 or BRCA2 
mutation, and 1 (2%) had a robust family history of BR-
CA-associated cancer but refused to undergo mutational 
testing.
At a dosage of 600 mg twice daily or more of olapa-
rib, there was an inhibition of PARP activity by more 
than 90%, measured in peripheral mononuclear cells.
The maximum tolerated dose (MTD) was 400 mg 
twice daily. Minimal adverse events were reported, 
mostly gastrointestinal and fatigue. Radiological or bio-
chemical (CA 125) response or stable disease for a pe-
riod of 4 months or more was achieved in 63% (12/19) 
of patients. An antitumor activity was reported in plat-
inum-resistant patients at a dosage underneath the rec-
ommended/maximum tolerated doses (21). These hope-
ful results were lately confirmed by an expanded cohort 
of 50 patients affected by BRCA1/2 mutation-associ-
ated advanced ovarian, primary peritoneal, and fallo-
pian tube cancers. With the administration of 200 mg 
twice daily a clinical benefit rate of 46% was achieved, 
with median response duration of 28 weeks (22). The 
overall clinical benefit rate increased notably with plati-
num sensitivity, and a significantly positive connection 
between the overall platinum-free interval and response 
to olaparib was found (p = 0.002), suggesting that PARP 
inhibition correlates with platinum sensitivity in addi-
tion to showing a benefit in resistant and refractory pa-
tients. Finally, in a dose-finding phase I trial in Japa-
nese population that included ovarian cancer patients, 
olaparib was well tolerated up to the 400 mg dosage, 
and preliminary evidence of antitumor activity was reg-
istered (23). Olaparib administration with topotecan, 
dacarbazine, paclitaxel, cisplatin, and gemcitabine has 
been described (24), with reports of an overlapping, 
dose-limiting toxicity, particularly myelosuppression, 
more pronounced compared with chemotherapeutic 
agents alone. Olaparib has also been associated with 
bevacizumab in a phase I trial in patients affected by ad-
vanced solid tumors, the hypothesis being that the ves-
sel regression produced by the anti-angiogenic agent in-
duces hypoxia and results in an intensification of DNA 
damage and genetic instability (25). Dean et al. reported 
the administration of growing doses of continuous oral 
olaparib (100, 200, and 400 mg) in combination with in-
travenous bevacizumab (10 mg/kg every 2 weeks).
The most common adverse events (AEs) related to 
olaparib were gastrointestinal (grade 1-2 nausea) and 
fatigue. Three serious AEs and /or dose-limiting toxici-
ties were reported (26). The latest phase I trial on olapa-
rib in association with chemotherapy was conducted by 
Van der Noll et al. and presented at the American Soci-
ety of Clinical Oncology (ASCO) meeting 2013 (27). In 
this study olaparib was associated with carboplatin, 
paclitaxel, or both (CPa) in 87 patients with advanced 
solid tumors, mostly breast (26%), melanoma (10%), 
and ovarian (7%), refractory to standard therapies. Es-
calating doses of olaparib capsule and tablet formula-
tions were studied. Twelve patients (14%) had known 
germline BRCA1/2 mutation (gBRCA1/2m). The most 
common AEs included myelosuppression (71%), nota-
bly neutropenia (54%), thrombocytopenia (26%), and 
fatigue (77%). Two doses were identified as tolerable: 
continuous olaparib 100 mg bid with weekly pacli-
taxel 80 mg/m2 and intermittent olaparib 200 mg bid 
(d1– 10) with CPa AUC4/175 mg/m2 every 3 weeks. 
Fourteen patients (16%) revealed an objective response 
(complete response 5%; partial response 11%); 28% 
had stable disease for ≥4 months with a greater drug ac-
tivity in BRCA1/2 mutated patients (complete response 
17%; partial response 33%). Tolerability was improved 
with intermittent olaparib. Given the promising results 
of phase I studies (see Table 2), phase II clinical trials 
involving patients affected by advanced/recurrent ovar-
ian cancer have been conducted (28-29) (Table 3).
A phase II international multicenter single-arm, 
open-label, sequential-dosing cohort study was initi-
ated, recruiting BRCA1/2 mutation carriers with recur-
rent EOC. This trial suggested a dose-response rela-
tionship; in fact greater olaparib activity was seen at a 
dose of 400 mg twice daily rather than at 100 mg twice 
daily (RECIST objective tumor response rate: 33% vs. 
12.5%, p < 0.05, progression free survival (PFS) 5.8 vs. 
1.9 months), with an acceptable toxicity profile (grade 
3 nausea in 7% and leucopoenia in 5% of patients). Re-
markably, two patients in the 400 mg cohort reached 
complete responses, whereas there was none in the low-
er dose group.
Favorable survival data in BRCA1/2 mutated pa-
tients treated with olaparib, have been recently reported 
in a multicenter non-comparative study conducted by 
Kaufman and presented at ASCO 2013 (30). Two hun-
dred ninety-eight heavily pretreated patients with ad-
vanced cancer refractory to standard therapy and with 
a gBRCA1/2m, including 193 patients with advanced 
ovarian cancer, received olaparib 400 mg bid (capsule) 
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ing the hypothesis that therapy focused against a geneti-
cally defined target is effective regardless of the ana-
tomic origin of the tumor. Gelmon et al. investigated the 
role of olaparib (400 mg) in a phase II single-arm study 
on patients affected by high-grade serous/undifferenti-
ated ovarian cancer and with unknown BRCA status 
or  BRCA-negative. The study also included a refer-
ence group known to have germline BRCA mutations. 
Ninety patients were enrolled (64 with ovarian cancer 
and 26 with breast cancer) and treated with olaparib 
400 mg bid. Biopsies were taken before starting treat-
ment, after two cycles, and at the time of progression. 
until disease progression. The median duration of treat-
ment was 5.5 months (range 1- 28.5 months). The most 
common AEs reported (generally of grade 1/2) were fa-
tigue (59%), nausea (59%), and vomiting (37%), where-
as the most common grade ≥3 AE was anemia (17%).
Among patients with ovarian cancer, the overall re-
sponse rate was 31%; 124 patients (64.4%) were alive 
1 year after treatment, with a progression-free interval 
of 6 months in 105 patients (PFS 54.6%). These re-
sults seem to indicate the antitumor activity of olaparib 
in monotherapy in gBRCAm patients affected by ad-
vanced cancer refractory to standard therapy, support-
Authors, year Patients Schedule Response rate Toxicity (grade I-II)
Toxicity
(grade III-IV)
Fong et al, 2013
15 BRCA1 or
BRCA2 OC
Olaparib:
100mg bid
200mg bid
400mg bid
600mg bid
PR/CR: 6%
PR/CR:40%; 
PR/CR: 26,6%
PR/CR: 6%
400mg bid group:
Diarrhea: 12%
Dyspepsia: 12%
Fatigue: 62%
Digeusia: 12%
400mg bid group:
Lymphopenia: 12%
Nausea:12%
Vomiting: 12%
Dizziness: 12%
van der Noll et al, 2013
50 advanced 
B R C A m 
OC, primary 
peritoneal and 
fallopian tube 
cancer
Dose-escalation cohort: 
from 40mg daily for 2 
of 3 weeks, to 600mg 
bid.
Dose-expansion cohort: 
200 mg twice daily in 
28-days cycles
PR/CR: 40%
SD:6%
Anemia: 6%
Nausea: 42%
Vomiting:18%
Diarrhea: 6%
Dyspepsia: 16%
Anorexia :16%
Fatigue:42%
Lymphopenia: 8%
Anemia: 8%
Nausea: 6%
Vomiting:2%
Diarrhea: 2%
Fatigue:4%
Martinek et al, 2010
12 solid tumor 
with BRCAm 
(including  OC)
Olaparib:
100mg bid
200mg bid
400mg bid
CR: 0%, PR:8,3%,
SD:0%,PD: 16,6%
CR: 0%, PR:0%, 
SD:16,6%, PD: 
8,3%
CR:0%, PR:0%,
SD:16,6%,  PD: 
33,3%
400mg bid group:
Nausea: 66%
Leukopenia: 50%
Anemia: 50%
Anorexia: 33%
Vomiting: 16%
Fatigue:16%
Not observed
Kaufman et al, 2013
12 solid tumor 
with BRCAm 
(including  OC)
Increasing doses 
of continuous oral 
Olaparib (100, 200 and 
400 mg) in combination 
with bevacizumab 
(10mg/kg every 2 
weeks)
NA No serious 
adverse effects 
were reported
OC: ovarian cancer; bid: twice daily; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease; NA: not available. 
Table 2. Phase I trials of Olaparib in EOC.
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Table 3. Phase II trials of Olaparib in EOC.
AUTHORS,
year PTS SCHEDULE RR PFS OS
TOXICITY
(grade III-IV)
Ledermann et al, 
2012 
57 BRCA1/2 m 
recurrent OC
Olaparib:
- 400mg bid (33 pts)
- 100mg bid (24 pts)
CR: 6%; 
PR: 27%; 
SD: 36%; 
PD: 30%;
CR:0%;   
PR: 13%; 
SD: 29%; 
PD:58%;
5.8 mths 
(median)
1.9 mths 
(median)
NA 400mg bid group:
Nausea: 6%
Fatigue: 3%
Anaemia: 3%
Vomiting: 3%
Neutropenia: 9%
Ledermann et al, 
2014 
265 pts recurrent 
OC
BRCA 1/2 m
OIaparib:
-400 mg bid
(136 pts)
Placebo
(129 pts)
NA
11.2 mths
(median)
4.3 mths
(median)
29.8 mths
(median)
27.8 mths
(median)
severe adverse events: 
18%
9%
(most common: bowel 
obstruction)
Liu et al, 2013 90 pts recurrent 
OC, TC, PeC
Olaparib:
-400 bid
(46 pts)
Olaparib 200 mg 
bid plus Cediranib 
30 mg 
(44 pts)
47.8%
79.6%
9.0 mths
(median)
17.7 mths
(median)
65% at 24 
mths
81% at 24 
mths
Combination group:
Diarrhoea: 23% 
Fatigue: 27% 
Hypertension:41% 
Kaufman et al, 
2014 
298 BRCA1/2 m 
OC, PrC, PC, BC
Olaparib:
-400 mg bid
(193 OC pts)
OC: 
31.1%
OC: 
7.0 mths
(median)
OC:
16.6 mths
OC group:
Nausea: 0.5%
Fatigue: 6.2%
Anaemia:18.7%
Vomiting: 2.6%
Abdominal pain: 7.3%
Descreased appetite: 1%
Oza et al, 2014 162 recurrent 
BRCA1/2 m OC
Olaparib 200 mg 
bid plus TXL175 
mg/mq and  
CBDCA AUC 
4 followed by 
Olaparib 400 mg 
bid (81 pts)
TXL175 mg/mq and 
CBDCA AUC 6 (81 
pts)
CR:10%
PR: 54%
OR: 64%
CR: 7%
PR: 51%
OR: 58%
12.2 mths 
(median)
9.6 mths
(median)
33.8 mths 
(median)
37.6 mths
(median)
Olaparib plus CHT group:
Headache: 1% 
Fatigue: 7% 
Neutropenia: 43%
PTS: patients; RR: response rate; PFS: progression free survival; OS: overall survival; m: mutated; nm: not-mutated; OC: ovarian cancer; OR: 
objective response; OOR: overall objective response; CR: complete response; PR: partial response; SD: steady disease; PD: progression of disease; 
mths: months; PLD: pegylated liposomal doxorubicin; I.A.: interim analysis; NA: not available OC: ovarian cancer; PrC: prostate cancer; PC: 
pancreatic cancer; BC: breast cancer; PeC: peritoneal cancer; OR: overall response.
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improved clinical outcome from anthracyclines such as 
PLD compared with not selected cases.
Notably, data from study of Kaye et al. confirmed 
that the higher dose of olaparib (400 mg twice daily) 
is suitable and more effective (35). Similar data for re-
lapsed ovarian cancer, irrespective of BRCA1/2 muta-
tions, were presented in a randomized, double blind, 
placebo-controlled phase II study by Ledermann et al. 
(36). Patients with platinum-sensitive, relapsed, high-
grade serous ovarian cancer were included in order to 
test the role of olaparib as maintenance treatment in this 
setting. Patients submitted to two or more platinum-
based regimens and with a partial or complete response 
to their most recent platinum-based schedule were re-
cruited to receive olaparib in monotherapy with the aim 
of evaluating its efficacy as maintenance treatment. The 
results from 256 randomized patients (136 received 
olaparib and 129 received placebo) showed an advan-
tage of approximately 4 months for olaparib versus 
placebo in median PFS (hazard ratio for progression or 
death 0.35; 95% CI, 0.25–0.49; p < 0.001), even if no 
significant differences in overall survival (OS) between 
the two treatment groups were reported (p = 0.75). 
Side effects more frequently reported in the olapa-
rib group than in the placebo one included nausea (68% 
vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 
14%), and anemia (17% vs. 5%); however, the majority 
of these were globally of grade 1 or 2.
Nevertheless, no significant difference in terms of 
OS between groups was found at interim analysis (38% 
mortality, meaning that 38% of the patients had de-
ceased; hazard ratio with olaparib, 0.94; 95% CI, 0.63–
1.39; p = 0.75). A preplanned subgroup analysis of 218 
out of 256 (82%) patients with a known gBRCAm from 
the trial by Ledermann et al. was recently performed; 
the results, presented at ASCO 2013 (37), suggested 
that olaparib (400 mg bid) may lead to a greater PFS 
and an OS benefit in those women with gBRCAm. In 
particular, gBRCA1/2m patients showed greater PFS 
benefit with olaparib maintenance versus placebo (me-
dian: 11.2 vs. 4.1 months; p < 0.001) and a signifi-
cant quality of life (QoL) improvement, as measured 
with the Trial Outcome Index (p = 0.03). Furthermore, 
even if at the interim analysis of OS the comparison of 
olaparib versus placebo in the overall population led to 
a hazard ratio of 0.88 with medians of 29.8 versus 27.8 
months, respectively, the subgroup analysis limited to 
gBRCAm patients resulted in an OS hazard ratio of 0.74 
(median: 34.9 for olaparib group vs. 31.9 months for 
placebo group). Moreover, olaparib was recently com-
bined with paclitaxel plus carboplatin (P/C) followed 
by olaparib as maintenance treatment in patients with 
platinum-sensitive recurrent serous ovarian cancer en-
rolled in a multicenter randomized open-label, phase 
II study (38). Arm A, which included patients submit-
ted to olaparib capsules plus P/C for 6 cycles followed 
by maintenance olaparib monotherapy, was compared 
with Arm B, which included patients receiving P/C 
alone for 6 cycles and no further therapy.
Of 162 patients randomized (n=81 per arm), 156 re-
ceived treatment (Arm A, n=81; Arm B, n=75) and 121 
started the maintenance/no further therapy phase (Arm 
A, n=66; Arm B, n=55). Olaparib + P/C (AUC4) fol-
lowed by maintenance olaparib showed a significant 
After BRCA testing, 17 patients showed BRCA muta-
tions. Consistent with previous studies, objective re-
sponses were reported in 7 of 17 patients with BRCA1 
or BRCA2 mutations (41%; 95% confidence interval 
(CI), 22–64) and 11 of 46 without mutations (24%; 
95% CI, 14–38), with a median response duration of 31 
weeks. In the ovarian-cancer cohort without BRCA1- 
or BRCA2-associated mutations, a CA- 125 response 
rate of 26% (95% CI, 15–42; 10 of 38) and a combined 
RECIST and CA-125 response rate of 30% (95% CI, 
19–44; 14 of 47) were recorded.
Of the totality of patients with ovarian cancer, the 
disease-control rate (partial response plus stable disease 
at 8 weeks) was 66% (42 of 64): in BRCA1- or BRCA2-
negative mutation cohorts the disease control rate was 
76% (13 of 17), and in BRCA1- or BRCA2-positive 
cohorts it was 62% (29 of 47). Responses were posi-
tively correlated with platinum sensitivity (radiological 
50%, biochemical 40%) compared with resistant/refrac-
tory disease (radiological 3.8%, biochemical 17.4%), 
consistent with other studies on BRCA1 or BRCA2 mu-
tation carriers. Adverse events were only of grade 1–2, 
including fatigue (70% of patients with ovarian cancer), 
nausea (66%), vomiting (39%), and decreased appetite 
(36%) (28). This study clearly showed that patients with 
platinum-sensitive high-grade serous ovarian cancer 
without a BRCA1/2 germline mutation responded to 
olaparib. This also suggests that a greater susceptibil-
ity to platinum and other DNA damaging agents can be 
considered as BRCA-like behavior. A possible explana-
tion for between platinum sensitivity and olaparib re-
sponse is that intra- and inter-strand platinum-DNA net-
work can generate torsion on the double helix and lead 
to DSBs (31), needing HR for proper and efficacious 
correction. Without repair, additional genomic damage 
is continued, leading to cell death.
Randomized phase II trials 
To address the role of olaparib as a second-line treat-
ment in BRCA1/2-mutated EOC patients, a three-arm 
study evaluating two different dosages of olaparib with 
the reference dose was planned. Ninety-seven patients 
with BRCA-mutated progressive or recurrent disease 
< 12 months after their last platinum administration 
were randomized in a 1:1:1 ratio to receive olaparib 200 
mg bid or 400 mg continuously or pegylated liposo-
mal doxorubicin (PLD) 50 mg/ m2intravenously (32). 
RECIST-assessed objective response rates were statisti-
cally comparable across the three arms (25%, 31%, and 
18% for olaparib 200 mg, olaparib 400 mg, and PLD, 
respectively). No statistically important differences 
in terms of PFS (olaparib 200 mg: 6.5 months; olaparib 
400 mg: 8.8 months; PLD: 7.1 months;hazard ratio 0.88, 
p=0. 6) were found, thus failing the primary end point of 
the study. Nevertheless, it should be underlined that the 
median PFS of 7.1 months of PLD observed in this trial 
is considerably greater than the 4 months expected, tak-
ing as a reference the randomized trial by Gordon et 
al. (33), in a comparable mix of platinum-resistant and 
platinum-sensitive cancers.
Accordingly, Adams and colleagues published ret-
rospective data  (34) that showed an increased activity 
of PLD in BRCA-mutated ovarian cancer patients, sug-
gesting that HR-deficient ovarian cancer may have an 
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ble side-effects occurred with cediranib plus olaparib, 
resulting in dose reductions in more than 75% of pa-
tients. Drug-related adverse events were more frequent 
with cediranib plus olaparib than with monotherapy, 
with 70% of patients having a grade 3 or higher event 
(diarrhoea, fatigue, hypertension). Another more recent 
multicenter phase II study enrolling 298 individuals 
with a germline BRCA1/2 mutation and recurrent can-
cer (ovarian, breast, pancreatic or prostate), investigated 
tumor response rate to olaparib in these patients (41). 
One hundred and seventy-eight out of 193 patients of 
ovarian cancer cohort, presented ovarian cancer, four 
had fallopian tube cancer, and 11 had primary perito-
neal cancer.
BRCA1 germline mutation affected 148 (77%) of 
those in the ovarian cancer cohort, while 44 patients 
(23%) had a BRCA2 mutation, and one had a germline 
mutation in both BRCA1 and BCRA2. These patients 
were heavily pretreated with meanly 4,3 prior regi-
mens and presented platinum-resistant disease. Patients 
received olaparib 400 mg twice per day until disease 
progression. The tumor response rate was 26.2% and 
31.1% for all and ovarian cancer patients respectively. 
Stable disease that continued ≥ 8 weeks was observed 
in 40.4% of OC patients.
Overall median duration of response was 208 
days (225 days for ovarian cancer). In these patients me-
dian PFS and OS were 7 and 16.6 months respectively. 
At 6 months of follow up, 54,6% of OC patients were 
progression free, while the proportion of patients alive 
at 12 months was
64.4%. The most common adverse events reported 
included fatigue, nausea, and vomiting with grade ≥ 3 
AEs considered causally related to olaparib in 30,9% 
of patients (41). In addition, in a latter randomized, 
open-label, phase 2 study 162 selected patients with 
platinum- sensitive, recurrent, high-grade serous ovar-
ian cancer submitted to up to three previous courses of 
platinum-based chemotherapy and who were progres-
sion free for at least 6 months before randomization 
were randomized to receive chemotherapy plus olapa-
rib or chemotherapy alone (42). Patients received either 
olaparib (200 mg capsules twice daily, administered 
orally on days 1–10 of each 21-day cycle) plus pacli-
taxel (175 mg/ m2, administered intravenously on day 
1) and carboplatin (area under the curve (AUC) 4 mg/
mL per min, administered intravenously on day 1), then 
olaparib monotherapy (400 mg capsules twice daily, 
given continuously) until progression (the olaparib plus 
chemotherapy group), or paclitaxel (175 mg/ m2 on day 
1) and carboplatin (AUC 6 mg/mL per min on day 1) 
followed by no further treatment (the chemotherapy 
alone group). One hundred and fifty-six patients were 
treated in the combination phase and 121 continued to 
the maintenance or no further treatment phase. BRCA 
mutation status was known for 107 patients of which 
41 (38%) had a BRCA mutation (20 in the olaparib 
plus chemotherapy group and 21 in the chemotherapy 
alone group). The study results showed a significantly 
longer PFS in the combination group (median 12.2 
months) than in the chemotherapy alone group (median 
9·6 months; HR=0.51, p=0.0012), especially in patients 
with BRCA mutations (HR=0.21,p=0.0015). Most 
common adverse events reported at least 10% more 
improvement in PFS versus P/C (AUC6) alone (hazard 
ratio 0.51, 95% CI, 0.34–0.77; p = 0.0012; median = 
12.2 vs. 9.6 months). Data on OS are still immature (to-
tal events: 14%). ORR was similar for Arm A and Arm 
B (64% vs. 58%). The most common AEs during the 
combination phase included alopecia (74% vs. 59% for 
Arm A versus Arm B, respectively), nausea (69% vs. 
57%), and fatigue (64% vs. 57%). There were no fatal 
AEs. 
Phase III trials are warranted to confirm these data. 
A second interim analysis of OS and a retrospective, 
preplanned analysis of data by BRCA mutation sta-
tus from the a randomised, double-blind, multicenter 
phase 2 study assessing the maintenance treatment with 
olaparib 400 mg twice daily versus placebo in plati-
num-sensitive recurrent ovarian cancer patients (36) 
has been recently conducted by Ledermann et al (36). 
BRCA status was known for 131 (96%) patients in the 
olaparib group versus 123 (95%) in the placebo group, 
of whom 74 (56%) versus 62 (50%) had a detrimental or 
suspected detrimental germline or tumour BRCA mu-
tation. A significantly longer PFS has been document-
ed in the olaparib group than in placebo one both for 
BRCA mutated patients (11,2 mo vs 4,3 mo for olapa-
rib and placebo group respectively, p<0.0001) and for 
wild-type BRCA (7,4 mo vs 5,5 mo for olaparib and 
placebo group respectively, p<0.0075), resulting in a 
greater benefit than that previously reported in the over-
all population (36). However, overall survival did not 
differ significantly between groups both for BRCA mu-
tated patients (p=0. 44) and wild-type BRCA (p =0. 96). 
Moreover, in the overall population, median time to first 
subsequent therapy or death was significantly longer in 
the olaparib population than in the placebo, regardless 
of BRCA mutation (p<0.0001). The most common ad-
verse events reported were grade1-2 fatigue and ane-
mia, with grade 3 or worse events in 10 (7%) patients of 
olaparib group versus four (3%) in the placebo one (39). 
These promising results have led to the approval of the 
drug in the maintenance treatment of platinum sensitive 
disease.
A recent randomized open-label phase II study per-
formed by Liu et al investigated the effects of the com-
bination of olaparib plus cediranib (n=44) versus olapa-
rib alone (n=46) in women with measurable platinum-
sensitive, relapsed, high-grade serous or endometrioid 
ovarian, fallopian tube, or primary peritoneal cancer or 
with detrimental germline BRCA1/2 mutations (40).
Cediranib is an antiangiogenic agent active against 
VEGF receptor type 1, 2, 3. 
Cediranib plus olaparib significantly improved 
progression-free survival (9.0 vs 17.7 months or olapa-
rib and combination respectively; p=0. 005) and the pro-
portion of patients who achieved an objective response 
compared with olaparib alone.
These results suggest that the combina-
tion of a PARP inhibitor and an anti-angiogenic drug 
could be synergistic and have increased activity in pa-
tients with platinum sensitive high-grade serous ovar-
ian cancers, as compared with either agent alone, con-
sistent with hypotheses generated by preclinical data. 
In exploratory analyses, the activity of cediranib plus 
olaparib seemed to be robust in both BRCA mutated 
and BRCA wild-type or unknown populations. Nota-
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response at 6 months. Partial response was seen in 9 
(16%) patients, and 19 (34%) patients had stable disease 
for at least 2 months (47). 
Additional phase I dose escalation and pharmacoki-
netic studies in advanced stage solid
cancers are currently ongoing (Table 1). Preliminary 
data from phase II studies of iniparib for the treatment 
of platinum-sensitive or resistant recurrent ovarian can-
cer show improvements in survival compared with his-
toric controls.
Notably, data from a phase II trial of iniparib 
(5.6 mg/ kg) in combination with gemcitabine (1000 mg/
m2 on days 1 and 8) and Carboplatin (AUC 4 on day 1) 
in women with recurrent platinum-sensitive ovarian can-
cer (ClinicalTrials.gov number NCT01033123) showed 
a 70.6% overall response rate in the first 17 patients en-
rolled (49). The same dosage has been used in a phase 
II study including platinum-resistant ovarian cancer pa-
tients (ClinicalTrials.gov number NCT01033292). Pre-
liminary data in 19 treated patients showed an objective 
response rate of 31.6% and PFS of 5.6 months, signifi-
cantly improved if compared with the response rates of 
prior studies in platinum-resistant patients (50). The re-
sults of a third, completed phase II study of patients with 
BRCA1- and BRCA2- associated advanced ovarian, fal-
lopian tube, or primary peritoneal cancers are eagerly 
awaited (ClinicalTrials.gov number NCT00677079). At 
present, iniparib has not yet been explored in phase III 
trials for the treatment of EOC. 
Veliparib and ovarian cancer 
Pharmacodynamics, pharmacokinetics, and metabo-
lism 
Veliparib (ABT-888) is a PARP inhibitor with excel-
lent potency (KI, 5.2 and 2.9 nmol/L, PARP-1/ PARP-
2) and oral bioavailability (51). In preclinical studies, 
veliparib was shown to be a potent inhibitor of PARP 
and was found to potentiate the effect of platinum 
agents, cyclophosphamide, and radiation in syngeneic 
and xenograft tumor models (52). It was also reported 
to have good bioavailability and the capability to cross 
the blood-brain barrier (53). 
The first phase 0 study performed under the guidance 
on exploratory investigational new drugs, issued by the 
U.S. Food and Drug Administration (FDA), was con-
ducted by the National Cancer Institute with veliparib. It 
was chosen because of its wide therapeutic index. Veli-
parib enhanced the activity of multiple DNA-damaging 
agents, including, irinotecan, carboplatin, cisplatin, cy-
clophosphamide, radiation, and temozolomide, in vari-
ous syngeneic and xenograft preclinical models (54). A 
validated pharmacodynamics assay was developed for 
assessing PARP inhibition by measuring PAR, a product 
of PARP. The pharmacokinetics and pharmacodynam-
ics were evaluated over a short time period after a sin-
gle dose of nontoxic veliparib (10, 25, and 50 mg, each 
tested in three patients). A significant reduction in PAR 
was seen at the 25 and 50 mg dose 3-6 h after dosing for 
both tumor and PBMC, respectively. Even at 24 h after 
dosing, a 49% reduction below baseline PAR level was 
reported (54).
Plasma veliparib concentrations were calculated 
with a liquid chromatography-mass spectrometry assay 
frequently with olaparib plus chemotherapy than with 
chemotherapy alone were typically of grade 1-2 with 
exception of neutropenia and included alopecia, nausea, 
neutropenia, diarrhea, headache, peripheral neuropathy 
and dyspepsia. The most common grade 3 or higher ad-
verse events during the combination phase were neutro-
penia (43% vs 35% in the olaparib plus chemotherapy 
group and chemotherapy alone one respectively) and 
anaemia (9% vs 7%, respectively). Serious adverse 
events were reported in 12 patients (15%) in the olapa-
rib plus chemotherapy group and 16 patients (21%) in 
the chemotherapy alone group; thus showing an accept-
able and manageable tolerability profile (42). 
Iniparib and ovarian cancer 
Pharmacodynamics, pharmacokinetics, and metabo-
lism 
Iniparib (BSI 201) belongs to the benzamide family 
of compounds; it is enzymatically reduced in malignant 
cells to the cytotoxic metabolite 4-iodo-3-nitrosoamide. 
Initial mechanistic studies showed that 4-iodo-3-nitros-
obenzamide inactivated PARP-1 by removing a single 
zinc finger. However, recent studies have shown that the 
mechanism of action of iniparib is not specific for the 
PARP-1 pathway. Iniparib also failed to potentiate the 
effects of topoisomerase, a hallmark of PARP inhibitors. 
It has been proposed that iniparib induces cell death by 
forming protein adducts with cysteine-containing pro-
teins, an interaction that is not limited to PARP. These 
protein adducts can cause sufficient alterations in intra-
cellular protein function to trigger cell death via a vari-
ety of pathways (32). Iniparib is administered intrave-
nously and excreted in the urine (43). The half-life of 
the drug in human studies is 4 minutes, with evidence of 
longer-lasting active metabolites. 
Clinical development 
Iniparib has been mostly studied in breast can-
cer, showing improvements in PFS and OS in a phase 
II trial for the treatment of metastatic triple-negative 
breast cancer
but failing to demonstrate improvement in survival in 
a phase III study (44-45). It was studied in combination 
with carboplatin and paclitaxel in a phase II trial involv-
ing women affected by uterine carcinosarcoma, but the 
response rate was not adequate to warrant further stud-
ies (46). Clinical data on iniparib in ovarian cancer are 
still limited, with preliminary but interesting data on tol-
erability and efficacy obtained from phase I-II studies. 
Phase III study results are not available. Phase I studies 
involving patients affected by solid tumors, conducted 
by Mahany et al. and Kopetz et al., have shown a maxi-
mum tolerated dose of 8 mg/kg for iniparib (47- 48).
The most common side effects reported were gastro-
intestinal and respiratory, with no report of grade 3 or 4 
toxicities. Of the 23 patients enrolled by Kopetz et al., 
6 patients had stable disease for about 2 months with 
iniparib administration (48). Mahany et al. enrolled 55 
patients with solid tumors and assigned to 1 of 4 com-
binations of iniparib plus topotecan or gemcitabine or 
temozolomide (TMZ) or carboplatin, according to phy-
sician preference. All regimens were well tolerated.
One patient with ovarian cancer showed complete 
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certain combination regimens (57). In addition to chem-
otherapeutic agents, veliparib has also been combined 
with anti-angiogenic agents. The rationale behind this 
combination is based on the observation that vascular 
endothelial growth factor receptor (VEGFR) inhibition 
may lead to increased DNA damage through down-
regulation of DNA repair proteins (58) and may stop 
the growth of tumor cells by blocking blood flow to the 
tumor.
The multicenter, dose-escalation phase I study of 
carboplatin, paclitaxel, bevacizumab, and ABT-888 
in treating patients with newly diagnosed stage II to 
IV ovarian epithelial cancer, fallopian tube cancer, or 
primary peritoneal cancer is actively enrolling patients 
(ClinicalTrials.gov identifier: NCT00989651). In the 
experimental regimen (Arm I) patients receive paclitax-
el over 3 hours, carboplatin over 30 minutes, and bev-
acizumab over 30 to 90 minutes (beginning in course 
2) on day 1. Patients also receive oral ABT-888 bid on 
days 1-21.
Patients belonging to Arm II receive paclitaxel over 
1 hour on days 1, 8, and 15. Patients also take carbopl-
atin, bevacizumab, and ABT-888 as in regimen I. For 
both arms treatment repeats every 21 days for 6 cours-
es, and patients then receive bevacizumab alone on day 
1. The treatment with bevacizumab repeats every 21 
days for 16 courses in the absence of disease progres-
sion or unacceptable toxicity.
The primary objectives of the study are to deter-
mine the MTD and dose-limiting toxicities of ABT-888 
when associated to carboplatin, paclitaxel, and bevaci-
zumab using two different treatment regimens, and the 
feasibility and the toxicity related to these regimens 
over four courses once the MTD is established. In the 
last multi-institutional phase I study, veliparib was com-
bined with low-dose fractionated whole abdominal ra-
diation (LDFWAR) to assess the safety profile of the 
combination in patients with advanced solid malignan-
cies and peritoneal carcinomatosis (59). Twenty-two 
patients were recruited, 8 patients with ovarian or fal-
lopian cancer. Patients were treated with veliparib for 
a total of 3 cycles. At the time of study enrollment, 
16 of 22 patients had exclusively abdominal disease and 
6 of 22 patients had both intra-abdominal and extra-ab-
dominal disease. In the subset of 8 ovarian and fallopian 
cancers, mPFS was 6.77 months and mOS was 17.54 
months compared with mPFS 2.71 months and mOS 
13.01 months in others. Patients with ovarian and fal-
lopian cancers had better QoL over time than those with 
other cancers. Treatment-related grade 3-4 toxicities in-
cluded lymphopenia (68%), anemia (9%), thrombocyto-
penia (14%), neutropenia (4%), leukopenia 9%), ascites 
(4%), vomiting (4%), and dyspnea (4%). No objective 
responses were observed. Thus, for some patients with 
advanced solid tumors and carcinomatosis, particularly 
in the ovarian and fallopian cancer subpopulation com-
bined veliparib and LDFWAR could be a well- tolerated 
regimen that resulted in prolonged disease stability (59). 
Recently a multicenter phase II trial presented at the 
SGO meeting reported the clinical activity of the single-
agent veliparib in BRCA mutation carriers affected by 
ovarian, fallopian tube or peritoneal cancer (60). The 
study enrolled 52 patients (50 of them evaluable for ef-
ficacy and toxicity) with recurrent or persistent measur-
validated by FDA guidelines (55). Majority of drug-re-
lated material was excreted in urine as unchanged drug. 
Clinical development 
Several studies have suggested that veliparib was 
effective in combination with chemotherapy for gy-
necologic cancers (56-58).  An open-label, multicenter, 
single-arm phase I combination study of ABT-888 and 
metronomic oral cyclophosphamide in patients with 
advanced malignancies was recently published by 
Kummar et al. The study included 11 patients affected 
by advanced ovarian cancer, treated with a dose esca-
lation design of the combined drugs. The study treat-
ment was well tolerated, with an acceptable profile of 
toxicity rates and the maximum tolerated dose (MTD) 
was established as veliparib 60 mg with cyclophospha-
mide 50 mg given once daily. Seven patients had a par-
tial response (5 patients with ovarian cancer) and an 
additional six patients had disease stabilization for at 
least six cycles (1 patient with ovarian cancer). These 
results suggest that also at lower doses, veliparib cre-
ated sufficient inhibition of PARP activity to provide 
benefit to BRCA-positive patients receiving DNA-dam-
aging chemotherapy (56). These positive results encour-
aged the beginning of a multicenter, randomized phase 
II study comparing metronomic cyclophosphamide 
alone versus metronomic cyclophosphamide in combi-
nation with veliparib in patients affected by advanced 
ovarian cancer and BRCA mutations, high-grade se-
rous ovarian cancers, triple-negative breast cancers, 
and low-grade lymphomas (ClinicalTrials.gov identi-
fier: NCT01306032). This study is ongoing, but is not 
recruiting participants. Veliparib has also been associ-
ated with topotecan in an open-label, single-arm phase 
I study testing the combination of ABT-888 adminis-
tered orally with topotecan hydrochloride administered 
intravenously in patients with advanced malignancies. 
Twenty-four patients with refractory solid tumors and 
lymphomas, including five patients with ovarian can-
cer, were enrolled. The study was carried out to deter-
mine the MTD, safety, pharmacokinetics, and pharma-
codynamics of the combination in these patients.
Various schedules and doses of intravenous topote-
can in combination with ABT-888 (10 mg) administered 
orally bid were evaluated.
All patients had previously received standard thera-
py and had evidence of disease progression.
Significant myelosuppression limited the ability to 
co-administer ABT-888 with standard doses of topote-
can, requiring dose reductions.
The MTD was established as topotecan 0.6 mg/
m2/d and ABT-888 10 mg bid on days 1 to 5 of 21-
day cycles. Myelosuppression was the principal toxic-
ity on this trial. This is the first clinical study showing 
significant reduction in PARP levels (more than 75%) 
in all three paired tumor biopsies compared with base-
line after administration of ABT-888 at 10 mg. Whether 
this degree of PARP inhibition is sufficient (or a higher 
degree of inhibition is needed) to derive clinical ben-
efit is currently unknown, making it difficult to define 
the ‘optimal biologic dose’ of ABT-888 in combination 
with chemotherapy. Escalating the PARP inhibitor dose 
to the MTD may not be necessary to derive clinical ben-
efit, especially given the narrow therapeutic index of 
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also been combined with temozolomide, carboplatin, 
carboplatin and paclitaxel, and cisplatin and pemetrexed 
(62–65). Rucaparib at 600 mg bid has been selected as 
the recommended Phase II dose in an ongoing Phase I/
II study in patients affected by various solid tumors (63-
68). Subsequent analysis described the patient popula-
tion with ovarian or primary peritoneal cancer enrolled 
in the Phase I portion. The treatment was well tolerated, 
drug-related adverse events resulting mild or moderate 
(Grade 1 (37%), Grade 2 (22%)) with low incidence of 
Grade 3 (6%) and no Grade 4. The safety profile in ovar-
ian and primary peritoneal patients was reliable with the 
overall profile in all patients and nausea, vomiting, diar-
rhea and fatigue events were controllable, with no dis-
continuations of the treatment. It has also demonstrated 
an enduring clinical benefit both in platinum-sensitive 
and resistant ovarian and primary peritoneal cancer pa-
tients. In fact, three RECIST PR and two GCIG CA-125 
responses has been accounted at the time of last analy-
sis with 4 out of them being platinum resistant. Disease 
control rate (CR, PR, SD at 12 weeks/24 weeks) were 
93% and 70% in germline BRCA ovarian cancer pa-
tients, respectively (69).
Rucaparib is currently undergoing further testing at 
the 600 mg bid dose in recurrent ovarian cancer as part 
of two clinical trials: ARIEL2 and ARIEL3. ARIEL2 is a 
phase II biomarker study of 180 patients with platinum-
sensitive, relapsed high-grade epithelial ovarian, fal-
lopian tube, or primary peritoneal cancer who have re-
ceived one or more prior platinum-based chemother-
apy regimens and whose last treatment regimen was 
platinum-based; fresh tumor biopsy and archival tumor 
are both required to participate. ARIEL3 is a phase III 
randomized trial of oral rucaparib versus placebo (2:1 
randomization) following platinum-based therapy in 
patients with platinum-sensitive high-grade serous or 
endometrioid epithelial ovarian, primary peritoneal, or 
fallopian tube cancer. Both trials are still recruiting pa-
tients. 
Niraparib and ovarian cancer 
Pharmacodynamics, pharmacokinetics, and metabo-
lism 
Niraparib, 2-{4-((3S)-piperidin-3-yl)phenyl}-2H-in-
dazole-7-carboxamide (MK4827), is a selective PARP-
1 and PARP-2 inhibitor, orally bioavailable, tested in 
a phase I trial in both patients with recurrent germline 
BRCA -ovarian cancer and patients with sporadic BR-
CA-proficient cancers (44-45). It presents a half maxi-
mum inhibitory concentration (IC50) of 3·8 nmol/L for 
PARP-1 and 2·1 nmol/L for PARP-2 (66). 
In a phase I dose-escalation study, mean plasma con-
centrations of niraparib peaked 3 to 4 h after a dose with 
a subsequent biphasic decrease in concentration. The 
mean terminal elimination half-life was 36.4 h (range 
32.8–46.0 h). Pharmacodynamic analyses confirmed 
PARP inhibition exceeded 50% at doses greater than 80 
mg/day, and antitumor activity was documented beyond 
doses of 60 mg/day (65-67). Niraparib inhibits tumor 
growth in models with loss of BRCA and PTEN func-
tion (70). 
able disease and germline mutations in BRCA1 (78%) 
or BRCA2 (22%). The majority of cancers (82%) were 
high-grade serous cell carcinomas. Patients underwent 
up to three prior therapies (with the exception of a prior 
PARP inhibitor). Thirty patients were platinum-resistant 
and 20% were platinum-sensitive.
Veliparib was started at 400 mg twice daily for 28 
days (one cycle), and dose reductions were allowed 
for toxicity. Overall response rate was 26%, including 
2 complete responses and 11 partial responses. The re-
sponse rate was 20% in platinum-resistant patients, 35% 
in platinum-sensitive ones, 26% and 27% in BRCA1 
and BRCA2 carriers respectively. At the time of the first 
analysis, median progression-free survival was 8.11 
months. At 6 months, 60% of patients were disease-free. 
Overall survival was estimated at 19.7 months. Toxic-
ity profile was satisfactory in these heavily pretreated 
patients. Only one case of grade 4 toxicity (thrombocy-
topenia) was reported. Grade 3 adverse events includ-
ed fatigue (n = 2), nausea (n = 2), leukopenia (n = 1), 
neutropenia (n = 1), dehydration (n = 1), and elevated 
alanine transaminase level (n = 1). Grade 2 toxicities, 
reported in more than 10% of patients, included nau-
sea (46%), fatigue (26%), vomiting (16%), and anemia 
(14%). Dose reductions for toxicity were required in 
24 patients (48%). The finding of somewhat activity of 
veliparib in various platinum-resistant patients with re-
current or persistent disease suggests the importance of 
further investigations.
Rucaparib and ovarian cancer 
Pharmacodynamics, pharmacokinetics, and metabo-
lism 
Rucaparib (CO338, AGO14699, and PF01367338) 
is another PARP-1 and PARP-2 oral inhibitor (with an 
inhibition constant of <5 nM) that has entered into clini-
cal trial testing for recurrent ovarian cancer showing an-
ti-ovarian cancer activity both in vitro and in vivo stud-
ies (60). The mean plasma half-life of oral rucaparib is 
approximately 17 h (61-62). In studies on female nude 
mice with heterozygous BRCA2 mutation inoculated 
with cancer cells with mutated BRCA1/2 or XRCC3 or 
with epigenetically silenced BRCA1, a 30-minute expo-
sure to 10 μM AG014699 caused more than 94% inhi-
bition of PARP activity, compared with untreated con-
trols. This result demonstrated that AG014699 freely 
permeates the cells, binds to and inactivates PARP, and 
that the inhibition persists during cell permeabilization 
and subsequent PARP enzyme stimulation.
Moreover, combination treatment with AG014699 
plus carboplatin reduced tumor growth better than treat-
ment with each drug alone (15). 
Clinical development 
The phase I study of oral rucaparib tested doses of 40 
mg up to 500 mg once per day continuously as well as 
240 mg to 840 mg bid; the recommended phase II dose 
of single-agent rucaparib was determined to be 600 mg 
bid.
Rucaparib demonstrated anticancer responses in an 
ovarian and peritoneal cancer subgroup, both in plat-
inum-resistant and platinum-sensitive recurrence (61). 
In addition to being explored as a single-agent, it has 
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tors. It is quickly orally bioavailable, with more than 
40% absolute oral bioavailability in rats when dosed 
in carboxylmethyl cellulose. Xenografted tumors that 
transport defects in DNA repair due to BRCA mutations 
or PTEN deficiency were greatly sensitive to oral BMN 
673 treatment at well tolerated doses (0.33 mg/kg or 0.1 
mg/kg once a day for 28 days) in mice. Synergistic or 
additive antitumor effects were also found when BMN 
673 was associated to temozolomide, SN38, or plati-
num drugs.
To assess the in vivo pharmacodynamics of BMN 
673, it has been administered orally in a single dose 
of 1 mg/ kg: intratumoral PAR levels drastically de-
creased at 2 and 8 hours following oral administration, 
with partial recovery of basal PAR levels at 24 hours 
after dosing, an effect probably due to the clearance of 
BMN 673 (71-72). 9.2 Clinical development An open-
label phase I study tested once-daily orally administered 
BMN 673 in patients with advanced or recurrent solid 
tumors, the primary objective of the study being to estab-
lish the MTD of daily oral BMN 673 (71). Thirty-nine 
patients were enrolled in 9 cohorts testing from 25 to 
1100 μg PO daily that defined a maximally tolerated 
dose of 1000 μg/day. The patient population included 23 
patients with either ovarian or primary peritoneal can-
cer, of which 17 presented a germline BRCA mutation. 
Dose-limiting thrombocytopenia occurred in 1 of 6 pa-
tients and in 2 of 5 patients at the 900 and 1100 μg/day, 
respectively. Potentially related AEs in >10% of patients, 
mostly of grade 1-2, included fatigue, nausea, flatulence, 
anemia, neutropenia, thrombocytopenia, and grade 1 al-
opecia. RECIST and/or CA-125 responses occurred at 
doses ≥100 μg/day in 11 out of 17 ovarian or perito-
neal cancer patients who had a germline BRCA muta-
tion. The recommended phase II dose was established at 
1000 μg/day PO (61). Currently, phase I and phase I -II 
studies, both on patients affected by advanced or recur-
rent solid tumors, are still accruing patients. Moreover, 
a phase III study testing BMN 673 in patients with ad-
vanced or metastatic breast cancer who are carriers of 
BRCA mutation and a phase II cohort study in germline 
BRCA mutation subjects with locally advanced and/or 
metastatic breast cancer are ongoing. Other PARP in-
hibitors Other PARP inhibitors that are or have been in 
clinical testing but do not have any associated ovarian 
cancer patient data or any ongoing or completed ovar-
ian cancer studies include AZD2461 (NCT01247168), 
CEP9722 (NCT00920595), E7449 alone or in several 
combinations (NCT01618136), E7016 in combination 
with temozolomide (NCT01127178), and INO-1001 
plus temozolomide (NCT00272415). 
Resistance to PARP inhibitors
 
The development of resistance to PARP inhibitors 
has been reported, and several mechanisms of potential 
resistance in BRCA-related tumors have been suggest-
ed.
Defects in BRCA function and HRR pathway give 
great genome instability in cancers. Therefore, as the 
disease progresses, these cancer cells tend to evolve 
into subpopulations, each of which may own distinct 
phenotypes with several degrees of response to PARP 
inhibitors.
Clinical development 
In a phase 1 dose-escalation multicentre study, 100 
patients with advanced solid tumours were enrolled (67). 
In part A, cohorts of three to six patients, enriched for 
BRCA1 and BRCA2 mutation carriers, received nira-
parib daily at ten escalating doses from 30 mg to 400 mg 
in a 21-day cycle to establish the maximum tolerated 
dose. In part B, the maximum tolerated dose was further 
investigated in patients with sporadic platinum-resistant 
high-grade serous ovarian cancer (HGSOC) and sporad-
ic prostate cancer. Sixty patients were enrolled in the part 
A of the study, including 49 patients with ovarian or peri-
toneal cancer. Twenty-two patients had known germline 
BRCA mutations and 27 were sporadic HGSC. A dose 
at of 300 mg/day was found to be the MTD. Two pa-
tients developed grade 4 thrombocytopenia at the 400 
mg dose level. DLTs during the first cycle of all dos-
es were grade 3 fatigue (one patient dosed at 30 mg/
day), grade 3 pneumonitis (one patient dosed at 60 mg/
day), and grade 4 thrombocytopenia (2 patients dosed at 
400 mg/day). Twenty of the 22 patients with germline 
BRCA mutations had RECIST measurable cancer, and 
8 of these 20 (40%; 95% CI, 19–64) had a confirmed 
RECIST and CA125 partial response; these patients re-
ceived doses of niraparib between 80 mg and 400 mg 
PO/day and the median response duration was 387 days 
(range 159-518 days). Ten patients with known BRCA 
mutations had platinum-sensitive cancer, and the ORR 
by RECIST and CA125 was 50% (95% CI, 19–81); me-
dian duration of the response was 431 days (range 159-
518 days). In the sporadic HGSC group that included 27 
patients, 22 patients had RECIST measurable 13 cancer; 
two of three patients with platinum-sensitive sporadic 
HGSC had responses by RECIST or CA125, and the 
doses received by these responders were 30 mg and 
60 mg. Of 19 patients with platinum-resistant sporadic 
HGCS, 3 responded according to RECIST or CA125 
(16%; 95% CI, 3– 40). Toxicities at the recommended 
phase II dose of 300 mg/day (50 patients tested) were 
mostly myelosuppression and gastrointestinal. 
Randomized trials 
Currently, a phase III study of niraparib versus pla-
cebo as maintenance therapy, called NOVA, is open 
and still accruing patients with platinum-sensitive re-
current HGSC who have achieved a partial or complete 
response to both their current and their penultimate 
platinum course. This is a double-blind study with a 
2:1 randomization of niraparib versus placebo for either 
germline BRCA or sporadic BRCA recurrent platinum-
sensitive HGSC. 
BMN 673 and ovarian cancer
  
Pharmacodynamics, pharmacokinetics, and metabo-
lism 
BMN 673 is an oral PARP-1 and PARP-2 inhibitor 
(70) (PARP1 IC50 = 0.57 nmol/L). It shows selective 
antitumor cytotoxicity and elicits DNA repair biomark-
ers at very lower concentrations than earlier generation 
PARP1/2 inhibitors (olaparib, rucaparib, veliparib). In 
vitro, BMN 673 selectively targets tumor cells with 
BRCA1- 2 or PTEN gene defects with 20- to more than 
200-fold superior potency than existing PARP inhibi-
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tory (78). Interestingly, the proportion of patients with a 
complete clinical remission at the end of first-line chem-
otherapy was higher in the BL population (90%) than 
in patients with the NBL signature (74%), although this 
was not statistically significant (p = 0.2). Additional 
studies are needed for the recognition of biomarkers to 
detect HR-deficient cancers. However, the finding of a 
gene expression profile that seems to relate with BR-
CAness may make it possible to eventually offer PARP 
inhibitors to a much bigger number of patients with 
epithelial ovarian cancer, regardless of their BRCA1 or 
BRCA2 mutation status.
Gene expression or immune-histochemical signa-
tures of deficiency of BRCA 1 and BRCA 2 expression or 
HR defects need also to be explored (26), and functional 
assays should be performed on tumor cells derived from 
ascites and circulating cells. In order to overcome resist-
ance to olaparib, PARP inhibitors have also been com-
bined with chemotherapeutic agents in several studies, 
and several trials investigating the combined regimens 
are still ongoing. In particular, because of the poten-
tial synergy of PARP inhibitors with inhibitors of other 
signaling pathways, combinations of PARP inhibitors 
with other targeted biologic agents have been explored 
in clinical trials, including trials combining PARP in-
hibitors with anti-angiogenic agents and with pi3-kinase 
(pi3k) inhibitors. A preclinical rationale exists for com-
bining anti-angiogenic agents: PARP inhibitors includ-
ing HR can be suppressed by hypoxia through down-
regulation of HR proteins, and PARP inhibitor sensi-
tivity is enhanced in hypoxic states (58-60). Olaparib 
was combined with bevacizumab to examine doses of 
continuous oral olaparib (100, 200, and 400 mg bid) in 
combination with 10 mg/kg of bevacizumab IV every 
2 weeks (72). Twelve patients were enrolled, and the 
most common toxicities observed were grade 1/2 nau-
sea and fatigue. The recommended phase II dose estab-
lished was olaparib 400 mg bid with bevacizumab 10 
mg/kg IV every 2 weeks.
Moreover, a phase I trial of oral cediranib, an 
oral VEGFR2 inhibitor, and olaparib enrolled 28 pa-
tients (20 ovarian cancer and 8 breast cancer patients) 
to four dose levels (73, 75). Cediranib may help keep 
cancer cells from growing by affecting their blood sup-
ply, whereas olaparib may stop cancer cells from grow-
ing abnormally. Thus, the combination of cediranib 
and olaparib may help to keep cancer from growing. 
Two DLTs (one grade 4 neutropenia and one grade 4 
thrombocytopenia) followed at the highest dose level 
(cediranib 30 mg daily and olaparib capsules 400 mg 
bid). The recommended phase II dose was cediranib 
30 mg daily and olaparib 200 mg bid. In the 18 ovar-
ian cancer patients with RECIST-evaluable disease, the 
ORR was 44%. Furthermore, we are still waiting for 
definitive results of a randomized phase II study test-
ing the combination of cediranib plus olaparib versus 
olaparib alone in women with platinum-sensitive recur-
rent ovarian cancer not previously submitted to anti-
angiogenic in the recurrent setting (NCT01116648). 
A rationale also exists for combining PARP inhibitors 
and PI3kinase inhibitors: a phase I study of olapa-
rib plus oral BKM120 (an oral PI3kinase inhibitor) is 
currently ongoing (NCT01623349). The foundation for 
this approach is based on the observation that activa-
BRCA deficiency may be reverted by changes in 
the mutational reading frame, resulting in produc-
tion of wild-type BRCA protein. Mounting evidence 
has proved that secondary somatic mutations of mu-
tated BRCA1 or BRCA2 genes restablish proficiency 
in HRR and give resistance to platinum chemotherapy 
and PARP inhibitors (73). These changes in the muta-
tional reading frame of BRCA may potentially occur 
through second mutations, compensatory mutations, or 
crossover (71-72). This may explain why not all BRCA-
mutation tumors respond to PARP inhibitors. Another 
mechanism hypothesized includes up-regulation of the 
p-glycoprotein efflux pomp reducing intracellular PARP 
inhibitor concentrations (74).
Ongoing studies are evaluating the chemo-sensitiv-
ity in women non-responders to PARP inhibitors and 
their mechanism of action.
Studies conducted on cell lines have demonstrat-
ed that an acquired secondary mutation can allow a 
BRCA1/2-deficient tumor to recover BRCA func-
tion and homologous recombination competency, so 
that PARP inhibition can no longer be synthetically le-
thal (75-76).
Remarkably, some patients who responded to olapa-
rib and then developed resistance have been described 
to retain sensitivity to further platinum-based treatment 
(77).
To describe a gene expression profile of BRCAness 
related to chemotherapy response and outcome in epi-
thelial ovarian cancer, Kostantinopolos et al. (78) made 
a publicly available microarray data set that includes 61 
patients affected by EOC with either sporadic disease or 
BRCA1/2 germline mutations and a second cohort of 70 
EOC patients submitted to exploratory laparotomy for, 
staging, diagnosis and debulking, followed by first-line 
platinum-based chemotherapy.
Combination with radiation-induced RAD51 foci 
formation and with PARP inhibitor responsiveness was 
assessed in cisplatin-resistant clones of the BRCA2-mu-
tated pancreatic cancer cell line Capan-1.
The BRCAness profile was confirmed in 70 patients 
enriched for sporadic disease to assess its association 
with outcome.
Association with platinum responsiveness was as-
sessed in platinum-sensitive and resistant tumor biopsy 
specimens from six patients with BRCA germline muta-
tions.
The BRCAness profile accurately predicted plati-
num responsiveness in 8 of 10 patient-derived tumor 
specimens and the correlation between PARP-inhibitor 
sensitivity and resistance in four out of four Capan-1 
clones. Moreover, in terms of the 70 patients with spo-
radic disease, patients with the BRCA-like (BL) profile 
showed improvements compared with patients with a 
non-BRCA-like (NBL) profile in disease-free survival 
(34 months vs. 15 months, respectively; p = 0 .013) and 
overall survival (72 months vs. 41 months, respectively; 
p=0.006), and this result was independent of standard 
prognostic factors such as age, grade, histology, stage, 
and debulking status (78). However, these data are not 
so strong as to assess whether the association between 
the BRCA-like profile and improved survival is indica-
tive of enhanced platinum responsiveness or, instead, 
might identify patients with a more weak natural his-
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The lack of survival improvement could be overcome 
by identifying a biomarker to direct therapy. Compared 
with the universal use of PARP inhibition, or the use of 
other biologic maintenance therapies, the BRCA1/2 test 
to direct personalized PARP inhibition treatment may 
symbolize a cost-reducing strategy, but further clinical 
trials are needed to confirm that BRCA1/2 mutations 
are predictive biomarkers to direct anti-PARP thera-
pies. Understanding the real mechanism of resistance to 
PARP would allow the definition of optimal sequenc-
ing of PARP inhibitors and platinum compounds. It is 
important that caution would be exercised for long-term 
use of these drugs, especially due to the lack of knowl-
edge on the effects of long-term inhibition of base exci-
sion repair in normal cells. The most investigated PARP 
inhibitor, olaparib, showed a significantly improved 
progression-free survival as maintenance therapy in the 
phase II randomized trial from Ledermann et al (36-37), 
with an extremely attractive toxicity profile, especially 
in those women with known germline BRCA mutations. 
These preliminary results encouraged further studies to 
characterize the subgroup of the ovarian cancer popu-
lation that will probably benefit from synthetic lethal-
ity–based therapy. Results of SOLO1 and SOLO2 ran-
domized trials, still in recruitment phase, will provide 
definitive results on the role of olaparib as maintenance 
therapy in women with newly diagnosed and recur-
rent BRCA-positive ovarian cancer. Moreover, with 
great nosiness we are waiting the results of the ongoing 
randomized, double-blind, multicenter, phase III trial 
of olaparib vs placebo in association with bevacizumab 
in patients not progressed after first-line chemotherapy 
plus bevacizumab for advanced high grade epithelial 
ovarian, fallopian tube, or primary peritoneal cancer 
(PAOLA1), to assess the role of this combination in this 
setting of patients. 
Furthermore, an immunological point of view on the 
effects of these new drugs could be a new scenario, sim-
ilarly to what concern for chemotherapy (85), in which 
the sole different of timing  (neoadjuvant vs adiuvant 
chemotherapy) could differently affect immune system 
against tumor. 
Another challenge will be the rational development 
of combinations of chemotherapy and PARP inhibitors 
with non-overlapping or minimally overlapping toxici-
ties and defining clinically optimal schedules using se-
quential therapy versus continuous or both. In conclu-
sion, a new individualized chemotherapeutic approach 
to patient based on the genomic characteristics of the 
cancer is urgently needed. Synthetic lethality is defined 
as a promising idea in ovarian cancer targeting. The best 
example of synthetic lethality is the interaction between 
PARP inhibition and BRCA deleterious mutations or 
BRCAness profile of sporadic ovarian cancer. 
Given the predictable increase in the global problem 
of cancer and limited health care resources, it is impera-
tive that researches will be conducted to define patient 
populations that will really benefit from novel thera-
pies. Appropriate identification of susceptible patient 
gene characteristics as a predictive and prognostic de-
gree of the efficacy of the PARP inhibitor targeting is 
paramount.
tion of the PI3K pathway occurs in as much as 70% 
of all ovarian cancers: 30% to 40% of type I ovarian 
cancers have activating mutations of PIK3CA (encod-
ing the p110 α subunit of PI3K), whereas 17% to 25% 
of type II ovarian cancers show genomic amplifica-
tion of the PIK3CA gene (79, 80). The PI3K pathway 
has been shown to be activated in a mouse model of 
BRCA1- related breast cancer, and the combination of 
olaparib and BKM120 was synergistic, leading to de-
layed tumor doubling compared with each agent alone 
(81). In addition, PI3K p110α inhibition was found to 
render BRCA1-proficient tumors sensitive to the anti-
cancer effects of olaparib using a murine breast cancer 
model (82). The combination of PARP inhibitors with 
chemotherapeutic or biologic agents could represent a 
favorable challenge by the increasing population of pa-
tients who may benefit from PARP inhibitors beyond 
BRCA-associated and/or HR-deficient cancers. Howev-
er, both the choice on the timing of the introduction of a 
PARP inhibitor and the decision about combining drugs 
and sequencing of administration should be accurately 
weighted on patient characteristics and tumor features, 
in order to increase patient benefits by minimizing treat-
ment-related toxicities (19).
 
Future directions 
The best way to counteract tumour growth is a syn-
ergistic action between different strategies. Surgery is 
the milestone of ovarian cancer treatment, however it 
needs to be followed by chemotherapy to maximize the 
efficacy. Similarly, immunologic effects have be studied 
both after chemotherapy and surgery. No data are com-
pleted now on the effect of molecular therapy alone or 
in association of standard treatment.
PARP inhibitors have been precursors in introduc-
ing the concept of personalized medicine in cancer ther-
apy, showing great clinical promise, especially in olapa-
rib-based studies. Nevertheless, some issues remain 
controversial. PARP inhibitors are poised to change how 
BRCA-related ovarian cancer is treated, but one of the 
major challenges remains the identification of patients 
who are most likely to benefit from treatment. At pre-
sent, relatively little biomarker information is available 
for the stratification of cancer patients eligible for PARP 
inhibitor therapy. Moreover, the tests that have been 
developed, such as PARP, g-H2AX foci, and RAD51 
(79-84), are too unwieldy for routine clinical use, al-
though they appear to be able to exactly define PARP 
inhibitor–sensitive tumors. The systematic use of these 
biomarkers in tumor biopsies or patient blood prior to, 
during, and after treatment would allow to discriminate 
patient populations responding or resistant to PARP in-
hibitors. Unfortunately, there is still no prospectively 
validated biomarker of HR-deficient ovarian cancers 
that accurately predict defective HR and responsiveness 
to PARP inhibitors, and this is an area of high priority 
for ovarian cancer research. The discover of biomark-
ers that can identify patients most likely to benefit from 
PARP inhibition has the potential to maximize benefit 
while minimizing health care costs.
PARP inhibition in an unselected population im-
proved PFS and prolonged disease control but an over-
all survival advantage has not been reported yet (83, 84). 
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